Roth Capital Issues Positive Forecast for CLRB Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Equities research analysts at Roth Capital lifted their Q1 2025 EPS estimates for shares of Cellectar Biosciences in a research note issued on Wednesday, December 11th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn ($0.18) per share for the quarter, up from their previous estimate of ($0.26). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.66) EPS, FY2026 earnings at ($0.62) EPS, FY2027 earnings at ($0.59) EPS and FY2028 earnings at ($0.18) EPS.

Cellectar Biosciences (NASDAQ:CLRB) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

A number of other analysts have also weighed in on the company. LADENBURG THALM/SH SH initiated coverage on Cellectar Biosciences in a research note on Thursday, December 5th. They issued a “buy” rating and a $13.00 target price for the company. Oppenheimer restated a “market perform” rating on shares of Cellectar Biosciences in a research report on Wednesday, December 11th. Finally, StockNews.com upgraded shares of Cellectar Biosciences to a “sell” rating in a research report on Thursday, September 26th.

Cellectar Biosciences Price Performance

CLRB stock opened at $0.26 on Monday. The business has a fifty day moving average price of $1.77 and a 200 day moving average price of $2.17. Cellectar Biosciences has a fifty-two week low of $0.23 and a fifty-two week high of $4.45. The stock has a market capitalization of $10.73 million, a price-to-earnings ratio of -0.15 and a beta of 0.89.

Hedge Funds Weigh In On Cellectar Biosciences

Several large investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. bought a new stake in Cellectar Biosciences during the 3rd quarter worth about $27,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Cellectar Biosciences during the 3rd quarter worth approximately $51,000. XTX Topco Ltd raised its stake in shares of Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 51,413 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Cellectar Biosciences by 3.3% during the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 11,266 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Cellectar Biosciences by 146.7% in the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock valued at $4,741,000 after buying an additional 708,191 shares during the period. Institutional investors and hedge funds own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.